Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2016

01.06.2016 | comment

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?

verfasst von: Dr. Ercan Müldür

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Summary

The incidence of prostate cancer is strongly correlated with age, with 35 % of patients aged 65–74 years and 25 % aged 75 years or older being affected [1]. Prostate cancer is third leading cause of cancer death among men aged 80 years and older. Of patients dying of prostate cancer, 41 % are aged 75–84 years, and 30 % above 85 years [2]. Fortunately treatment for metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the last few years.
Literatur
1.
Zurück zum Zitat Horner M, Ries L, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2006, based on November 2008 SEER data submission. In: Nationanal Cancer Institute; 2009. Horner M, Ries L, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2006, based on November 2008 SEER data submission. In: Nationanal Cancer Institute; 2009.
2.
Zurück zum Zitat Ries, LAG, Melbert, D, Krapcho, M, et al. SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute, 2008, based on December 2009 SEER data submission, posted to the SEER web site 2008. Ries, LAG, Melbert, D, Krapcho, M, et al. SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute, 2008, based on December 2009 SEER data submission, posted to the SEER web site 2008.
3.
Zurück zum Zitat Ryan CJ, Smith MR, Bono de, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRefPubMed Ryan CJ, Smith MR, Bono de, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRefPubMed
4.
Zurück zum Zitat Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.CrossRefPubMedPubMedCentral Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Tannock IF, Wit R de, Berry WR, Horti J, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMed Tannock IF, Wit R de, Berry WR, Horti J, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.CrossRefPubMed
6.
Zurück zum Zitat Bono JS de, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefPubMed Bono JS de, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefPubMed
7.
Zurück zum Zitat Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411.CrossRefPubMed Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411.CrossRefPubMed
8.
Zurück zum Zitat Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–e414.CrossRefPubMed Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–e414.CrossRefPubMed
9.
Zurück zum Zitat Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242.CrossRefPubMed Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242.CrossRefPubMed
10.
Zurück zum Zitat Anderson J, Van Poppel H, Bellmunt J, et al. Chemotherapy for older patients with prostate cancer. BJU Int. 2007;99:269.CrossRefPubMed Anderson J, Van Poppel H, Bellmunt J, et al. Chemotherapy for older patients with prostate cancer. BJU Int. 2007;99:269.CrossRefPubMed
11.
Zurück zum Zitat Mourey L, Gravis G, Sevin E, et al. Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG PO3 trial led by Unicancer (abstract). ASCO Genitourinary Cancer Symposium. 2014. Mourey L, Gravis G, Sevin E, et al. Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG PO3 trial led by Unicancer (abstract). ASCO Genitourinary Cancer Symposium. 2014.
12.
Zurück zum Zitat Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003;2:167.CrossRefPubMed Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003;2:167.CrossRefPubMed
13.
Zurück zum Zitat Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009;55:1368.CrossRefPubMed Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009;55:1368.CrossRefPubMed
14.
Zurück zum Zitat Fossä SD. A randomized phase II trail comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. Front Radiat Ther Oncol. 2008;41:108.CrossRefPubMed Fossä SD. A randomized phase II trail comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. Front Radiat Ther Oncol. 2008;41:108.CrossRefPubMed
15.
Zurück zum Zitat Kellokumpu-Lehtinen P-L, Tampere: 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Finland Lancet Oncol. 2013;14(2):117–124. Kellokumpu-Lehtinen P-L, Tampere: 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Finland Lancet Oncol. 2013;14(2):117–124.
16.
Zurück zum Zitat Bono JS de, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147. Bono JS de, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147.
17.
Zurück zum Zitat Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24:2402.CrossRefPubMedPubMedCentral Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24:2402.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Maines F, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015 Dec; 96(3):498–506. Maines F, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015 Dec; 96(3):498–506.
19.
Zurück zum Zitat Bono JS de, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364;1995.CrossRefPubMedPubMedCentral Bono JS de, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364;1995.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187.CrossRefPubMed Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187.CrossRefPubMed
Metadaten
Titel
Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
verfasst von
Dr. Ercan Müldür
Publikationsdatum
01.06.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0265-5

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe